Here are Antti’s comments on the first results of Orion’s ODM-212 candidate 
Orion announced over the weekend preliminary results from the Phase I/II clinical trial of the cancer drug candidate ODM-212. Based on the results presented at the ASCO congress, the drug candidate has been well-tolerated by patients and has shown preliminary signs of efficacy in hard-to-treat cancers. The clinical program for the drug candidate started in late 2022, so it is still in a very early stage of development.